CN101385810B - Traditional Chinese medicine composition containing chinemys reevesii for treating dermatomyositis and preparation thereof - Google Patents

Traditional Chinese medicine composition containing chinemys reevesii for treating dermatomyositis and preparation thereof Download PDF

Info

Publication number
CN101385810B
CN101385810B CN200710145411XA CN200710145411A CN101385810B CN 101385810 B CN101385810 B CN 101385810B CN 200710145411X A CN200710145411X A CN 200710145411XA CN 200710145411 A CN200710145411 A CN 200710145411A CN 101385810 B CN101385810 B CN 101385810B
Authority
CN
China
Prior art keywords
dermatomyositis
medicine composition
chinese medicine
carapax
fructus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200710145411XA
Other languages
Chinese (zh)
Other versions
CN101385810A (en
Inventor
陆春玲
李云鹏
秦拢
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hebei Yiling Pharmaceutical Research Institute Co Ltd
Original Assignee
Hebei Yiling Pharmaceutical Research Institute Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hebei Yiling Pharmaceutical Research Institute Co Ltd filed Critical Hebei Yiling Pharmaceutical Research Institute Co Ltd
Priority to CN200710145411XA priority Critical patent/CN101385810B/en
Publication of CN101385810A publication Critical patent/CN101385810A/en
Application granted granted Critical
Publication of CN101385810B publication Critical patent/CN101385810B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

The invention provides a traditional Chinese medicine composition which contains tortoise plastron and is used for treating dermatomyositis and a preparation thereof. The dermatomyositis is classified as 'flaccidity syndrome' by the theory of collateral diseases of the Chinese traditional medicine, and the pathogenesis of the dermatomyositis is mainly the deficiency of the spleen and the kidney, no source for the production and transformation of qi and blood, inability of the weakened body resistance to conquer pathogen, and obstruction of the collaterals of muscles and skin by wind cold dsmpness, thus affecting the liver, the kidney and the spleen and causing the yin collaterals stasis of internal organs, qi-blood disharmony, and malnutrition of the limbs, skin, tendons and channels. Aiming at treating syndromes of yin deficiency of the liver and the kidney, and weakness and stasis of collaterals and channels caused by the dermatomyositis, the Chinese traditional medicine composition determines the treatment based on differentiation of symptoms and signs by the theory of the collateral deficiency of Chinese traditional medicine, and is made from dried rehmannia root, the tortoise plastron, turtle shell, eclipta, glossy privet fruit, sweet wormwood, dogwood fruit, mistletoe, Chinese wolfberry, moutan bark, earth worm and batryticated silkworm to invigorate the liver and kidney and replenish vital essence for removing obstruction from the channels. Clinical studies prove that the traditional Chinese medicine composition can treat the dermatomyositis effectively.

Description

A kind of Chinese medicine composition and preparation thereof that contains the treatment dermatomyositis of Carapax et Plastrum Testudinis
Technical field
The present invention relates to a kind of Chinese medicine composition and preparation thereof that contains the treatment dermatomyositis of Carapax et Plastrum Testudinis, belong to the Chinese herbal and crude drugs preparations technical field.
Background technology
Dermatomyositis (dermatomyositis, DM) be a kind of striped muscle that mainly involves, apyetous inflammatory myopathy based on lymphocytic infiltration, belong to one of autoimmunity connective tissue disease, the primary disease course of disease is long, the disability rate height is difficult to radical cure, and doctor trained in Western medicine is mainly used glucocorticoid and immunosuppressant treatment.The traditional Chinese medical science is classified as primary disease characteristic symptom and the major lesions mechanism that " myopathy " more meets primary disease.
The dermatomyositis pathogenesis is mainly deficiency of spleen and stomach, and no resource of generating and transforming QI and blood weakened body resistancely can not be driven heresy, and wind and cold is damp and hot to accumulate the network that hinders skin, and then influences the Liver and kidney spleen, causes the internal organs yin collaterals stasis of blood and stagnates, and is qi-blood disharmony, and limbs skin muscle arteries and veins loses supports.The primary disease exopathogen is based on wet, and dampneee being viscous and lingering easily checks mechanism of qi, the humidity hysteresis stagnation of QI, muscle skin meridians impatency is obstructed, its form of expression can have difference, the wet or heat of holding concurrently, or the damp and hot poison that accumulates, or cold-damp go in heat-transformation; Interior-deficiency head blames in the spleen kidney, sees with the deficiency of YIN more, or is the natural endowment deficiency, and cloudy liquid is plain to be lost, or the labor desire is excessively, the smart damage of cloudy consumption, or diseases caused by exogenous pathogenic factor are damp and hot, consumption impairment of QI the moon.The course of disease with the passing of time, deficiency of YIN affecting YANG can be seen syndrome of yang deficiency of spleen and kidney again and wait; No matter invade in the exopathogen, it is puckery still to seek the deficiency of YIN, and no matter sick pathogenic heat noxious dampness is just violated network, still pathogen usually intruding into collateral in protracted disease, and venation is a basic pathology mechanism of dermatomyositis for disease, also is to cause primary disease to show effect repeatedly, delays the principal element that difficulty heals.The clinical manifestation of dermatomyositis: muscle weakness, involve extremity more, can involve cervical region and oblongata myasthenia, even muscle weakness can appear breathing in severe patient; Can accompany skin turgor, or erythema or erythema; Part patient's myalgia.The limb muscle atrophy can appear in late period, and tendon reflex disappears, and severe patient can cause pulmonary fibrosis or paralysis of respiratory muscle death.
Hepatic and renal YIN deficiency, the empty type dermatomyositis that stagnates of battalion's network, clinical manifestation is: onset is slow, and the course of disease is prolonged for a long time, and the speckle color is floating red, and myalgia is indistinct, and muscular atrophy is weak, can accompany and become thin, and has a dizzy spell soreness of the waist and knees, dry throat and mouth, the few tongue of red tongue, thready and rapid pulse.Former because: pyretic toxicity is delaied, and impairment of YIN consumption liquid, or the plain body hepatic and renal YIN deficiency, muscles lose supports, thus see that muscular atrophy is weak, become thin, have a dizzy spell, symptoms such as soreness of the waist and knees, dry throat and mouth, deficiency of YIN resistance network, as seen myalgia is indistinct; Deficiency-heat is fumigated skin, and the network of skin is injured, so see that macule is floating red; The few tongue of red tongue, thready and rapid pulse is the hepatic and renal YIN deficiency, resembling of hyperactivity of fire hindered in Tianjin.
Modern medicine is used glucocorticoid, immunoglobulin, immunosuppressant and multivitamin treatment more at present, and wherein glucocorticoid is most widely used general, and is cheap.But the glucocorticoid effect lacks specificity, and life-time service produces various untoward reaction to human body; Immunoglobulin, immunosuppressant then cost an arm and a leg, and are not suitable for life-time service.Tradition Chinese medicine dermatomyositis is also had nothing in common with each other, and the rule of treatment differs.
Summary of the invention
The invention provides a kind of Chinese medicine composition and preparation thereof that contains the treatment dermatomyositis of Carapax et Plastrum Testudinis.The common pathogenesis of venation pathological changes of dermatomyositis is that the QI and blood or the resistance of seminal fluid numbness of channels is obstructed, so collateral dredging is total Therapeutic Principle.
In the Chinese medicine composition of the present invention, the Radix Rehmanniae, Herba Ecliptae, Fructus Ligustri Lucidi, Fructus Corni, Fructus Lycii enriching yin and nourishing kidney, profit ruton network; Carapax Trionycis 5 Carapax et Plastrum Testudinis nourishing YIN for suppressing the hyperactive YANG are brought down a fever, and go into network and search heresy; The saturating network of Herba Artemisiae Annuae fragrance heat clearing away draws heresy and goes out; Bombyx Batryticatus, Pheretima, Cortex Moutan heat clearing away collateral dredging.
The invention provides a kind of Chinese medicine composition that contains the treatment dermatomyositis of Carapax et Plastrum Testudinis, it is characterized in that being making by the crude drug of following weight portion ratio:
Radix Rehmanniae 6-30 Carapax et Plastrum Testudinis 9-30 Carapax Trionycis 9-20 Herba Ecliptae 9-20
The parasitic 15-30 of Fructus Ligustri Lucidi 9-20 Herba Artemisiae Annuae 6-15 Fructus Corni 12-20
Fructus Lycii 12-30 Cortex Moutan 9-15 Pheretima 9-15 Bombyx Batryticatus 9-15
Preferably, Chinese medicine composition of the present invention is to be made by the crude drug of following weight portion ratio:
Radix Rehmanniae 10-25 Carapax et Plastrum Testudinis 12-25 Carapax Trionycis 10-17.5 Herba Ecliptae 10-20
The parasitic 15-25 of Fructus Ligustri Lucidi 10-20 Herba Artemisiae Annuae 7.5-12 Fructus Corni 15-20
Fructus Lycii 15-25 Cortex Moutan 9-15 Pheretima 9-15 Bombyx Batryticatus 9-15
More preferably, Chinese medicine composition of the present invention is to be made by the crude drug of following weight portion ratio:
The Radix Rehmanniae 12 Carapax et Plastrum Testudiniss 14 Carapax Trionycis 11 Herba Ecliptaes 11 Fructus Ligustri Lucidi 11
Herba Artemisiae Annuae 8 Fructus Corni 14 parasitic 18 Fructus Lycii, 16 Cortex Moutans 10
Pheretima 10 Bombyx Batryticatus 10
Or make by the crude drug of following weight portion ratio:
The Radix Rehmanniae 28 Carapax et Plastrum Testudiniss 28 Carapax Trionycis 19 Herba Ecliptaes 19 Fructus Ligustri Lucidi 19
Herba Artemisiae Annuae 24 Fructus Corni 19 parasitic 29 Fructus Lycii, 29 Cortex Moutans 14
Pheretima 14 Bombyx Batryticatus 14
Or make by the crude drug of following weight portion ratio:
The Radix Rehmanniae 7 Carapax et Plastrum Testudiniss 10 Carapax Trionycis 9 Herba Ecliptaes 9 Fructus Ligustri Lucidi 9
Herba Artemisiae Annuae 6 Fructus Corni 12 parasitic 15 Fructus Lycii, 12 Cortex Moutans 9
Pheretima 9 Bombyx Batryticatus 9
Or make by the crude drug of following weight portion ratio:
The Radix Rehmanniae 21 Carapax et Plastrum Testudiniss 22 Carapax Trionycis 16 Herba Ecliptaes 16 Fructus Ligustri Lucidi 16
Herba Artemisiae Annuae 11 Fructus Corni 17 parasitic 24 Fructus Lycii, 23 Cortex Moutans 12
Pheretima 12 Bombyx Batryticatus 12
The preparation formulation of Chinese medicine composition of the present invention is decoction, powder, capsule, tablet, pill or oral liquid.
The dosage form of Chinese medicine composition of the present invention adopts conventional preparation method preparation, and for example, the preparation technology of Fan Biting " pharmacy of Chinese materia medica " (Shanghai Science Press 1997 December the 1st edition) record makes the acceptable regular dosage form of pharmaceutics.
In the application of the present invention, described Chinese medicine composition is a kind of in decoction, powder, capsule, tablet, pill, the oral liquid formulations, for above-mentioned dosage form can be realized, need when these dosage forms of preparation, to add the pharmacy acceptable auxiliary, for example: filler, disintegrating agent, lubricant, suspending agent, binding agent, sweeting agent, correctives, antiseptic, substrate etc.Filler comprises: starch, pregelatinized Starch, lactose, mannitol, chitin, microcrystalline Cellulose, sucrose etc.; Disintegrating agent comprises: starch, pregelatinized Starch, microcrystalline Cellulose, carboxymethyl starch sodium, crospolyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, cross-linking sodium carboxymethyl cellulose etc.; Lubricant comprises: magnesium stearate, sodium lauryl sulphate, Pulvis Talci, silicon dioxide etc.; Suspending agent comprises: polyvinylpyrrolidone, microcrystalline Cellulose, sucrose, agar, hydroxypropyl emthylcellulose etc.; Binding agent comprises, starch slurry, polyvinylpyrrolidone, hydroxypropyl emthylcellulose etc.; Sweeting agent comprises: saccharin sodium, Aspartane, sucrose, cyclamate, enoxolone etc.; Correctives comprises: sweeting agent and various essence; Antiseptic comprises: parabens, benzoic acid, sodium benzoate, sorbic acid and its esters, benzalkonium bromide, fixed, the Folium eucalypti globueli (Eucalyptus globulus Labill.) wet goods of acetic acid chloroethene; Substrate comprises: PEG6000, PEG4000, insect wax etc.For making above-mentioned dosage form can realize pharmacy of Chinese materia medica, need when these dosage forms of preparation, to add acceptable other adjuvant of pharmacy (adjuvant of each dosage form record among the Fan Biting " pharmacy of Chinese materia medica ", Shanghai Science Press December in 1997 the 1st edition).
Preferably, the dermatomyositis of traditional Chinese medicine composition for treating of the present invention is a hepatic and renal YIN deficiency, the empty type dermatomyositis that stagnates of battalion's network.We are because of liver and kidney tonifying, and the YIN nourishing collateral dredging so the treatment hepatic and renal YIN deficiency is sought the empty type dermatomyositis that stagnates of network, has better effect.
Be confirmation clinical drug curative effect of the present invention, the decoction that use prepares according to embodiment 1 described method (to call in the following text: medicine of the present invention) carried out following clinical observation:
One, clinical diagnosis standard
Standard formulation with reference to propositions in 1975 such as Bohan
1, main standard:
A, typical dermatosis (the purplish red erythra of eyelid), peripheral vessel expansion and finger are stretched side squama erythema or extremity trunk erythema.
B, muscular strength reduce flesh tenderness and scleroma, slow movement and the obvious amyotrophy of extremity peri position.
Inflammatory cell infiltration, edema are seen in c, flesh biopsy, muscle fiber hyalinosis or cavity necrosis, and the muscle fiber thickness differs, interstitial fibrosis, muscle fiber orthogenesis etc.
D, sero-enzyme GOT, GPT, LDH, aldolase etc. surpass normal value 5%.
The existing of e, electromyography showed myositis (use 17-hydroxy-11-dehydrocorticosterone or spasmolytic etc. and then can influence positive findings).
2, minor criteria
A, calcific deposit.
B, dysphagia.
3, diagnositc decision
Possess 3 in 5 of the main standard, or 2 of main standard add 2 of minor criterias, promptly be diagnosed as dermatomyositis (skin symptom is not polymyositis for a long time).
Main standard have only 1 and (or) 2 times, then possess 1 of 2 of main standard or main standard and add 2 of minor criterias and promptly be diagnosed as dermatomyositis.
Special-shaped: with the polymyositis or the dermatomyositis of malignant tumor.
Except: struvite muscle illness or dermatomyositis that reason is clear and definite.
4, traditional Chinese medical science disease diagnostic criteria:
Hepatic and renal YIN deficiency, battalion's network is empty to stagnate:
Primary symptom: (1) limb muscle atrophy is unable, (2) skin turgor or erythema (3) arthralgia of the extremities and irritability
Inferior disease: (1) red tongue, few tongue, (2) thready and rapid pulse,
(3) have a dizzy spell or soreness of the waist and knees (4) dysphoria with feverish sensation in the chest palms and soles
Two of above primary symptoms or more than add two of time diseases or more than be diagnosed as this type.
Two, data and method
1, physical data:
This research is carried out in Hebei Yi Ling hospital, and all cases meet above-mentioned doctor trained in Western medicine criterion.Age excludes this research greater than 65 years old and the organ injury persons such as severe cardiac, liver, kidney (in the inpatient therapeutic process send out survivor except) of occurring together.Medicine group 95 examples of the present invention are inpatient; Male's 21 examples wherein, women's 74 examples; 16~61 years old age, average 42 years old; The course of disease is smaller or equal to 1 year person's 8 example, 1~3 year person's 31 example, and 4~7 years person's 41 examples, more than or equal to 8 years person's 15 examples, wherein 48 examples met hepatic and renal YIN deficiency, the empty traditional Chinese medical science disease diagnostic criteria that stagnates of battalion's network.Matched group 37 examples also are inpatient; Male's 9 examples wherein, women's 28 examples; 15~60 years old age, average 41 years old; The course of disease is smaller or equal to 1 year person's 3 example, 1~3 year person's 14 example, and 4~7 years person's 17 examples, more than or equal to 8 years person's 3 examples, wherein 16 examples met traditional Chinese medical science hepatic and renal YIN deficiency, the traditional Chinese medical science disease diagnostic criteria of the empty type that stagnates of battalion's network.Treat preceding two groups of patients at aspect difference not statistically significants such as sex, age, the course of disease, degree of being in a bad way.
2, Therapeutic Method:
2.1 medicine group of the present invention: take medicine of the present invention, 600 milliliters of every days, divide twice decoction being taken warmly sooner or later.Glucocorticoid treatment: prednisone 0.8-1.5 mg/day/kilogram.To wherein meet hepatic and renal YIN deficiency, the empty traditional Chinese medical science disease diagnostic criteria that stagnates of battalion's network be divided into the S1 subgroup, all the other do not meet hepatic and renal YIN deficiency, the empty traditional Chinese medical science disease diagnostic criteria that stagnates of battalion's network be divided into the S2 subgroup, above-mentioned two hypotypes all adopt identical treatment measure.
2.2 matched group: QINGHAOBIEJIATANG (Herba Artemisiae Annuae 6 grams, Carapax Trionycis 15 grams, Radix Rehmanniae 12 grams, the Rhizoma Anemarrhenae 6 grams, Cortex Moutan 9 grams, Carapax Trionycis adds clear water and is decocted first for 1 liter, boils decoction and add other crude drug continuation decoctions to the half an hour of boiling, and intense fire decocts to boiling, continue slow fire boiling half an hour, filter 300 milliliters of extracting juice.Add 500 milliliters in water again, repeat to decoct once, filter, 300 milliliters of extracting juice merge the medicine juice of twice decoction, and mixing amounts to 600 milliliters, divides twice decoction being taken warmly sooner or later.) and glucocorticoid treatment, consumption is the same.
3, be 3 months the course of treatment course of treatment.
4, observation index: deflorescence situation, muscular strength, creatine phosphokinase.That observes untoward reaction, relapse rate and hormone simultaneously removes the situation of subtracting smoothly.The muscular strength grade scale is with reference to the grade scale of Britain Medical Res Council.
5, curative effect determinate standard: " the new Chinese medicine clinical research guideline (dermatomyositis) " of Ministry of Public Health promulgation formulated with reference to nineteen ninety-five.
The clinical recovery standard: erythra disappears fully, and the muscle Myodynamia recovery is normal, and it is normal that myocardium enzyme is recovered.
Clinical produce effects standard: the erythra major part disappears, and the muscle muscular strength increases the 2-3 level, and 2 or above measured value descend and surpass 50% in the myocardium enzyme.
Clinical effective standard: erythra partly disappears, and the muscle muscular strength increases the 1-2 level, and myocardium enzyme has 2 or above decline 25-50%.
Clinical invalid standard: erythra does not have minimizing, and muscular strength increases by 1 grade of less than, the myocardium enzyme equal less than 25% that descends.
6, statistical method
Two groups of curative effects relatively adopt rank test, and total effective rate relatively adopts X 2 test.Adopt the SPSS10.0 statistical software, there is statistical significance P<0.05 for difference; Two subgroup curative effects more also adopt rank test, and there is statistical significance P<0.05 for difference;
Three, result
1, medication therapy groups of the present invention and matched group curative effect are relatively
Table 1 liang group clinical curative effect analysis (routine number, %)
Grouping The example number Recovery from illness Produce effects Effectively Invalid Total effective rate (%)
Medicine group of the present invention 95 ?3(3.2) 47(49.5) 29(30.5) 16(16.8) 83.2
Matched group 37 ?3(2.7) 10(27.0) 14(37.8) 12(32.4) 67.6
Two groups of general curative effects relatively adopt rank test, p=0.014, so medicine group of the present invention and matched group have marked difference on general curative effect, and the matched group that is better than evident in efficacy of medicine of the present invention; Two groups of total effective rates relatively adopt X 2 test, p=0.024, so there were significant differences on total effective rate in matched group for medicine group of the present invention, the effective percentage of medicine group of the present invention is significantly higher than matched group.
2, different TCM Syndrome Type curative effects relatively
The different TCM Syndrome Type efficacy analysis of table 2 (routine number, %)
Grouping The example number Recovery from illness Produce effects Effectively Invalid Total effective rate (%)
The S1 group 48 2(4.2) 28(58.3) 13(27.1) 5(10.4) 89.58
The S2 group 47 1(2.1) 19(40.4) 16(34.0) 11(23.4) 76.60
Two groups of general curative effects relatively adopt rank test, p=0.034, so the S1 group has marked difference with the S2 group on general curative effect, medicine of the present invention is sought the hepatic and renal YIN deficiency that is better than evident in efficacy of the empty type dermatomyositis that stagnates of network for hepatic and renal YIN deficiency, the empty stagnant type dermatomyositis of battalion's network.
Four, conclusion
Chinese medicine composition of the present invention can effectively be treated dermatomyositis, the treatment hepatic and renal YIN deficiency, and the empty type dermatomyositis that stagnates of battalion's network has better effect.
The specific embodiment
Example below in conjunction with the preparation of medicine decoction of the present invention, powder, capsule, tablet, pill, oral liquid illustrates the specific embodiment of the present invention.
Embodiment 1:
The Radix Rehmanniae 21 gram Carapax et Plastrum Testudiniss 22 gram Carapax Trionycis 16 gram Herba Ecliptaes 16 gram Fructus Ligustri Lucidi 16 grams
The parasitic 24 gram Fructus Lycii of the Herba Artemisiae Annuae 11 Keshan Fructus Evodiaes 17 grams 23 gram Cortex Moutans 12 grams
Pheretima 12 gram Bombyx Batryticatus 12 grams
Preparation method: Carapax et Plastrum Testudinis and Carapax Trionycis add clear water and are decocted first for 1 liter, boil decoction and add other crude drug to the half an hour of boiling and continue to decoct, and intense fire decocts to boiling, and continue slow fire boiling half an hour, filter 300 milliliters of extracting juice.Add 500 milliliters in water again, repeat to decoct once, filter, 300 milliliters of extracting juice merge the medicine juice of twice decoction, and mixing amounts to 600 milliliters, promptly get decoction, divides morning and evening twice decoction being taken warmly.
Embodiment 2:
The Radix Rehmanniae 12 gram Carapax et Plastrum Testudiniss 14 gram Carapax Trionycis 11 gram Herba Ecliptaes 11 gram Fructus Ligustri Lucidi 11 grams
The parasitic 18 gram Fructus Lycii of the Herba Artemisiae Annuae 8 Keshan Fructus Evodiaes 14 grams 16 gram Cortex Moutans 10 grams
Pheretima 10 gram Bombyx Batryticatus 10 grams
Preparation method: formulation method is total to the porphyrize foam routinely, makes powder.
Embodiment 3:
The Radix Rehmanniae 28 gram Carapax et Plastrum Testudiniss 28 gram Carapax Trionycis 19 gram Herba Ecliptaes 19 gram Fructus Ligustri Lucidi 19 grams
The parasitic 29 gram Fructus Lycii of the Herba Artemisiae Annuae 24 Keshan Fructus Evodiaes 19 grams 29 gram Cortex Moutans 14 grams
Pheretima 14 gram Bombyx Batryticatus 14 grams
Preparation method: formulation method is made capsule routinely.
Embodiment 4:
The Radix Rehmanniae 7 gram Carapax et Plastrum Testudiniss 10 gram Carapax Trionycis 9 gram Herba Ecliptaes 9 gram Fructus Ligustri Lucidi 9 grams
The parasitic 15 gram Fructus Lycii of the Herba Artemisiae Annuae 6 Keshan Fructus Evodiaes 12 grams 12 gram Cortex Moutans 9 grams
Pheretima 9 gram Bombyx Batryticatus 9 grams
Preparation method: formulation method is made tablet routinely.
Embodiment 5:
The Radix Rehmanniae 16 gram Carapax et Plastrum Testudiniss 18 gram Carapax Trionycis 13 gram Herba Ecliptaes 13 gram Fructus Ligustri Lucidi 13 grams
The parasitic 21 gram Fructus Lycii of the Herba Artemisiae Annuae 10 Keshan Fructus Evodiaes 15 grams 20 gram Cortex Moutans 11 grams
Pheretima 11 gram Bombyx Batryticatus 11 grams
Preparation method: formulation method is made pill routinely.
Embodiment 6:
The Radix Rehmanniae 25 gram Carapax et Plastrum Testudiniss 25 gram Carapax Trionycis 17 gram Herba Ecliptaes 17 gram Fructus Ligustri Lucidi 17 grams
The parasitic 27 gram Fructus Lycii of the Herba Artemisiae Annuae 13 Keshan Fructus Evodiaes 18 grams 26 gram Cortex Moutans 13 grams
Pheretima 13 gram Bombyx Batryticatus 13 grams
Preparation method: formulation method is made oral liquid routinely.

Claims (8)

1. Chinese medicine composition that contains the treatment dermatomyositis of Carapax et Plastrum Testudinis is characterized in that being being made by the crude drug of following weight portion ratio:
Radix Rehmanniae 6-30 Carapax et Plastrum Testudinis 9-30 Carapax Trionycis 9-20 Herba Ecliptae 9-20
The parasitic 15-30 of Fructus Ligustri Lucidi 9-20 Herba Artemisiae Annuae 6-15 Fructus Corni 12-20
Fructus Lycii 12-30 Cortex Moutan 9-15 Pheretima 9-15 Bombyx Batryticatus 9-15.
2. the Chinese medicine composition of treatment dermatomyositis according to claim 1 is characterized in that being being made by the crude drug of following weight portion ratio:
Radix Rehmanniae 10-25 Carapax et Plastrum Testudinis 12-25 Carapax Trionycis 10-17.5 Herba Ecliptae 10-20
The parasitic 15-25 of Fructus Ligustri Lucidi 10-20 Herba Artemisiae Annuae 7.5-12 Fructus Corni 15-20
Fructus Lycii 15-25 Cortex Moutan 9-15 Pheretima 9-15 Bombyx Batryticatus 9-15.
3. the Chinese medicine composition of treatment dermatomyositis according to claim 1 is characterized in that being being made by the crude drug of following weight portion ratio:
The Radix Rehmanniae 21 Carapax et Plastrum Testudiniss 22 Carapax Trionycis 16 Herba Ecliptaes 16 Fructus Ligustri Lucidi 16
Herba Artemisiae Annuae 11 Fructus Corni 17 parasitic 24 Fructus Lycii, 23 Cortex Moutans 12
Pheretima 12 Bombyx Batryticatus 12.
4. the Chinese medicine composition of treatment dermatomyositis according to claim 1 is characterized in that being being made by the crude drug of following weight portion ratio:
The Radix Rehmanniae 12 Carapax et Plastrum Testudiniss 14 Carapax Trionycis 11 Herba Ecliptaes 11 Fructus Ligustri Lucidi 11
Herba Artemisiae Annuae 8 Fructus Corni 14 parasitic 18 Fructus Lycii, 16 Cortex Moutans 10
Pheretima 10 Bombyx Batryticatus 10.
5. the Chinese medicine composition of treatment dermatomyositis according to claim 1 is characterized in that being being made by the crude drug of following weight portion ratio:
The Radix Rehmanniae 7 Carapax et Plastrum Testudiniss 10 Carapax Trionycis 9 Herba Ecliptaes 9 Fructus Ligustri Lucidi 9
Herba Artemisiae Annuae 6 Fructus Corni 12 parasitic 15 Fructus Lycii, 12 Cortex Moutans 9
Pheretima 9 Bombyx Batryticatus 9.
6. according to the arbitrary described Chinese medicine composition of claim 1-5, the preparation formulation that it is characterized in that this Chinese medicine composition is decoction, powder, capsule, tablet, pill or oral liquid.
7. Chinese medicine composition as claimed in claim 6 is characterized in that described decoction, powder, capsule, tablet, pill or oral liquid contain one or more pharmaceutically acceptable excipient.
8. according to the arbitrary described Chinese medicine composition of claim 1-5, it is characterized in that described dermatomyositis is a hepatic and renal YIN deficiency, the empty type dermatomyositis that stagnates of battalion's network.
CN200710145411XA 2007-09-11 2007-09-11 Traditional Chinese medicine composition containing chinemys reevesii for treating dermatomyositis and preparation thereof Active CN101385810B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN200710145411XA CN101385810B (en) 2007-09-11 2007-09-11 Traditional Chinese medicine composition containing chinemys reevesii for treating dermatomyositis and preparation thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN200710145411XA CN101385810B (en) 2007-09-11 2007-09-11 Traditional Chinese medicine composition containing chinemys reevesii for treating dermatomyositis and preparation thereof

Publications (2)

Publication Number Publication Date
CN101385810A CN101385810A (en) 2009-03-18
CN101385810B true CN101385810B (en) 2011-04-20

Family

ID=40475616

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200710145411XA Active CN101385810B (en) 2007-09-11 2007-09-11 Traditional Chinese medicine composition containing chinemys reevesii for treating dermatomyositis and preparation thereof

Country Status (1)

Country Link
CN (1) CN101385810B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105596392A (en) * 2016-01-15 2016-05-25 白云兵 Medicine for tonifying kidney

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1336204A (en) * 2001-07-19 2002-02-20 晏二仔 Health-care products for oral or external use
CN1385175A (en) * 2001-05-11 2002-12-18 黎陆明 Medicine for treating dermatomyositis
CN1478518A (en) * 2003-05-15 2004-03-03 兰金初 Medicine for treating lupus erythematosus, dermatomyositis, dermatos clerosis and sicca syndrome

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1385175A (en) * 2001-05-11 2002-12-18 黎陆明 Medicine for treating dermatomyositis
CN1336204A (en) * 2001-07-19 2002-02-20 晏二仔 Health-care products for oral or external use
CN1478518A (en) * 2003-05-15 2004-03-03 兰金初 Medicine for treating lupus erythematosus, dermatomyositis, dermatos clerosis and sicca syndrome

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
郭刚等.硬皮病从络病论治.《新中医》.2007,第39卷(第3期), *
陆春玲等.从湿论治多发性肌炎.《光明中医》.2002,第17卷(第98期), *

Also Published As

Publication number Publication date
CN101385810A (en) 2009-03-18

Similar Documents

Publication Publication Date Title
CN102512552B (en) Traditional Chinese medicine composition for treating exogenous fever
CN103041145B (en) Traditional Chinese medicine composition for treating exogenous fever
CN100488539C (en) Pharmaceutical composition for promoting blood circulation and preparation method thereof
CN104491459A (en) Traditional Chinese medicine composition for treating tumors
CN102327395B (en) Pharmaceutical composition for treating postpartum persistent lochia and preparation method thereof
CN107669991A (en) A kind of pharmaceutical composition for reducing serum uric acid level and preparation method thereof
CN102579975B (en) Traditional Chinese medicine mixture for treating psoriasis
CN101385810B (en) Traditional Chinese medicine composition containing chinemys reevesii for treating dermatomyositis and preparation thereof
CN103394002A (en) Medicinal composition for treating cutaneous pruritus as well as preparation method and application thereof
CN106039109A (en) Traditional Chinese medicinal liquor for preventing and treating cold dampness accumulation pattern rheumatoid arthritis
CN101385812B (en) Traditional Chinese medicine composition containing epimeddium for treating dermatomyositis and preparation thereof
CN101385805B (en) Traditional Chinese medicine composition containing cicada-shell for treating dermatomyositis and preparation thereof
CN102406893A (en) Chinese patent medicine for treating psoriasis.
CN101385836B (en) Traditional Chinese medicine composition containing poria cocos for treating dermatomyositis and preparation thereof
CN104800675A (en) Medicament for treating active ulcerative colitis
CN102579895B (en) Traditional Chinese medicine composition for treating psoriasis
CN104622995A (en) Pharmaceutical composition for treating chronic superficial gastritis and preparation method of pharmaceutical composition
CN103585414A (en) Pharmaceutical composition for treating sciatica and osteoporosis
CN101385820B (en) Traditional Chinese medicine composition containing ephedra for treating dermatomyositis and preparation thereof
CN103536842A (en) Mixture for treating psoriasis
CN102727766A (en) Traditional Chinese medicinal preparation for treating comprehensive hemorrhoids, and preparation method thereof
CN102552824B (en) Traditional Chinese medicine prepared prescription for treating psoriasis
CN106880673A (en) It is a kind of to treat Chinese medicine composition of coronary heart disease and preparation method thereof
CN106581468A (en) Preparation method of traditional Chinese medicine capable of treating gastric ulcer
CN102416099A (en) Traditional Chinese medicine for treating psoriasis

Legal Events

Date Code Title Description
PB01 Publication
C06 Publication
SE01 Entry into force of request for substantive examination
C10 Entry into substantive examination
GR01 Patent grant
C14 Grant of patent or utility model